A Parathyroid-Gut Axis: Hypercalcemia and the Pathogenesis of Gastrinoma in Multiple Endocrine Neoplasia 1.
Journal
Molecular cancer research : MCR
ISSN: 1557-3125
Titre abrégé: Mol Cancer Res
Pays: United States
ID NLM: 101150042
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
28
01
2021
revised:
24
02
2021
accepted:
23
03
2021
pubmed:
28
3
2021
medline:
27
1
2022
entrez:
27
3
2021
Statut:
ppublish
Résumé
Patients with multiple endocrine neoplasia 1 (MEN1) syndrome have a germline mutation in the
Identifiants
pubmed: 33771883
pii: 1541-7786.MCR-21-0073
doi: 10.1158/1541-7786.MCR-21-0073
doi:
Substances chimiques
MEN1 protein, human
0
Proto-Oncogene Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
946-949Informations de copyright
©2021 American Association for Cancer Research.
Références
Tomasetti C, Vogelstein B. Cancer etiology. variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science. 2015;347:78–81.
Dreijerink KMA, Timmers HTM, Brown M. Twenty years of menin: emerging opportunities for restoration of transcriptional regulation in MEN1. Endocr Relat Cancer. 2017;24:T135–45.
Caslini C, Yang Z, El-Osta M, Milne TA, Slany RK, Hess JL. Interaction of MLL amino terminal sequences with menin is required for transformation. Cancer Res. 2007;67:7275–83.
Imachi H, Murao K, Dobashi H, Bhuyan MM, Cao X, Kontani K, et al. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance. Breast Cancer Res Treat. 2010;122:395–407.
Dreijerink KMA, Groner AC, Vos ESM, Font-Tello A, Gu L, Chi D, et al. Enhancer-mediated oncogenic function of the menin tumor suppressor in breast cancer. Cell Rep. 2017;18:2359–72.
Malik R, Khan AP, Asangani IA, Cieslik M, Prensner JR, Wang X, et al. Targeting the MLL complex in castration-resistant prostate cancer. Nat Med. 2015;21:344–52.
Verges B, Boureille F, Goudet P, Murat A, Beckers A, Sassolas G, et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab. 2002;87:457–65.
Anlauf M, Schlenger R, Perren A, Bauersfeld J, Koch CA, Dralle H, et al. Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. Am J Surg Pathol. 2006;30:560–74.
Lubensky IA, Debelenko LV, Zhuang Z, Emmert-Buck MR, Dong Q, Chandrasekharappa S, et al. Allelic deletions on chromosome 11q13 in multiple tumors from individual MEN1 patients. Cancer Res. 1996;56:5272–8.
Pannett AA, Thakker RV. Somatic mutations in MEN type 1 tumors, consistent with the Knudson "two-hit" hypothesis. J Clin Endocrinol Metab. 2001;86:4371–4.
Weil RJ, Vortmeyer AO, Huang S, Boni R, Lubensky IA, Pack S, et al. 11q13 allelic loss in pituitary tumors in patients with multiple endocrine neoplasia syndrome type 1. Clin Cancer Res. 1998;4:1673–8.
Debelenko LV, Zhuang Z, Emmert-Buck MR, Chandrasekharappa SC, Manickam P, Guru SC, et al. Allelic deletions on chromosome 11q13 in multiple endocrine neoplasia type 1-associated and sporadic gastrinomas and pancreatic endocrine tumors. Cancer Res. 1997;57:2238–43.
Hessman O, Lindberg D, Einarsson A, Lillhager P, Carling T, Grimelius L, et al. Genetic alterations on 3p, 11q13, and 18q in nonfamilial and MEN 1-associated pancreatic endocrine tumors. Genes Chromosomes Cancer. 1999;26:258–64.
Perren A, Anlauf M, Henopp T, Rudolph T, Schmitt A, Raffel A, et al. Multiple endocrine neoplasia type 1 (MEN1): loss of one MEN1 allele in tumors and monohormonal endocrine cell clusters but not in islet hyperplasia of the pancreas. J Clin Endocrinol Metab. 2007;92:1118–28.
Anlauf M, Perren A, Henopp T, Rudolf T, Garbrecht N, Schmitt A, et al. Allelic deletion of the MEN1 gene in duodenal gastrin and somatostatin cell neoplasms and their precursor lesions. Gut. 2007;56:637–44.
Anlauf M, Perren A, Meyer CL, Schmid S, Saremaslani P, Kruse ML, et al. Precursor lesions in patients with multiple endocrine neoplasia type 1-associated duodenal gastrinomas. Gastroenterology. 2005;128:1187–98.
Kloppel G, Anlauf M, Perren A, Sipos B. Hyperplasia to neoplasia sequence of duodenal and pancreatic neuroendocrine diseases and pseudohyperplasia of the PP-cells in the pancreas. Endocr Pathol. 2014;25:181–5.
Pritchard DM. Pathogenesis of gastrinomas associated with multiple endocrine neoplasia type 1. Gut. 2007;56:606–7.
Yu R, Nissen NN, Dhall D, Heaney AP. Nesidioblastosis and hyperplasia of alpha cells, microglucagonoma, and nonfunctioning islet cell tumor of the pancreas: review of the literature. Pancreas. 2008;36:428–31.
Henopp T, Anlauf M, Schmitt A, Schlenger R, Zalatnai A, Couvelard A, et al. Glucagon cell adenomatosis: a newly recognized disease of the endocrine pancreas. J Clin Endocrinol Metab. 2009;94:213–7.
Solloway MJ, Madjidi A, Gu C, Eastham-Anderson J, Clarke HJ, Kljavin N, et al. Glucagon couples hepatic amino acid catabolism to mTOR-dependent regulation of alpha-cell mass. Cell Rep. 2015;12:495–510.
Ray JM, Squires PE, Curtis SB, Meloche MR, Buchan AM. Expression of the calcium-sensing receptor on human antral gastrin cells in culture. J Clin Invest. 1997;99:2328–33.
Boron WF, Boulpaep EL. Medical physiology. 2016.
Goebel SU, Peghini PL, Goldsmith PK, Spiegel AM, Gibril F, Raffeld M, et al. Expression of the calcium-sensing receptor in gastrinomas. J Clin Endocrinol Metab. 2000;85:4131–7.
Feng J, Petersen CD, Coy DH, Jiang JK, Thomas CJ, Pollak MR, et al. Calcium-sensing receptor is a physiologic multimodal chemosensor regulating gastric G-cell growth and gastrin secretion. Proc Natl Acad Sci U S A. 2010;107:17791–6.
Declich P, Belloni J, Tavani E, Omazzi B, Bellone S, Bortoli A, et al. The morphlogical and immunohistochemical spectrum of gastric biopsies of patients with absorptive hypercalciuria. BMJ Open Gastroenterol. 2014;1:e000004.
Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012;95:98–119.
Norton JA, Venzon DJ, Berna MJ, Alexander HR, Fraker DL, Libutti SK, et al. Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT. Ann Surg. 2008;247:501–10.
Kovesdi A, Toth M, Butz H, Szucs N, Sarman B, Pusztai P, et al. True MEN1 or phenocopy? Evidence for geno-phenotypic correlations in MEN1 syndrome. Endocrine. 2019;65:451–9.
Giusti F, Cianferotti L, Gronchi G, Cioppi F, Masi L, Faggiano A, et al. Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to multiple endocrine neoplasia syndrome type 1 (MEN1). Endocrine. 2016;52:495–506.
Ceglia L, Harris SS, Rasmussen HM, Dawson-Hughes B. Activation of the calcium sensing receptor stimulates gastrin and gastric acid secretion in healthy participants. Osteoporos Int. 2009;20:71–8.
Mohr H, Pellegata NS. Animal models of MEN1. Endocr Relat Cancer. 2017;24:T161–77.
Veniaminova NA, Hayes MM, Varney JM, Merchant JL. Conditional deletion of menin results in antral G cell hyperplasia and hypergastrinemia. Am J Physiol Gastrointest Liver Physiol. 2012;303:G752–64.